HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Cosmetic safety guidance

This article was originally published in The Rose Sheet

Executive Summary

FDA should convene a panel of experts with no financial ties to the cosmetics industry to develop guidance on cosmetic safety substantiation, the Environmental Working Group says in a March 7 letter to Center for Food Safety & Applied Nutrition Director Robert Brackett. FDA reiterated a plan to develop a draft guidance to implement warning statements for cosmetic products containing ingredients not shown to be safe in a Feb. 3 letter to CTFA. Agency also said it would consider taking compliance action against firms marketing unsafe ingredients without warning labels, a measure EWG supports, the letter adds. Advocacy group filed a petition with FDA last year requesting the agency halt the unlawful distribution of misbranded, adulterated and unlabeled cosmetics (1"The Rose Sheet" June 14, 2004, p. 3)...

You may also be interested in...



Carcinogens In Cosmetics Need Oversight, Environmental Group Claims

Cosmetics manufacturers should reformulate products containing known or possible carcinogens and educate consumers on ingredient safety and alternatives to potentially harmful personal care products, according to Environmental Working Group, a non-profit research organization

Post-Brexit UK Risks Being ‘Left Out In The Cold’ As EU Coordinates Action On Shortages

The UK is not alone in experiencing drug shortages, as data from across Europe show, but its departure from the EU makes it more difficult to respond to supply chain pressures, according to new research.

Dr Reddy’s Knocked Back On Rituximab In US

Dr Reddy’s has received a complete response letter from the US FDA, knocking back its proposed rituximab biosimilar rival to Rituxan.

Latest Headlines
See All
UsernamePublicRestriction

Register

RS012886

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel